Study record
MOTS-c improves osteoporosis by promoting the synthesis of type I collagen in osteoblasts via TGF-β/SMAD signaling pathway
Che N, Qiu W, Wang JK et al. · Eur Rev Med Pharmacol Sci · 2019
CellsMOTS-c administeredEvidence tier D
What this study reported
In hFOB1.19 osteoblasts, MOTS-c was reported to increase cell viability and the expression of TGF-β, SMAD7, COL1A1 and COL1A2. The increase in collagen genes was partially reversed by knockdown of TGF-β or SMAD7.
Limitations
Single cell line with no in-vivo bone outcomes despite the osteoporosis framing of the title.
Study record
| Study model | Cell study (in vitro) |
|---|---|
| Substance studied | MOTS-c administeredSynthetic MOTS-c was given to cells, animals or people. |
| Species | human |
| System studied | hFOB1.19 human osteoblast cell line |
| Population | Not reported |
| Design | Cell culture experiments |
| Sample size as reported | Not reported |
| Control group | untreated cells; TGF-β or SMAD7 knockdown |
| Route (data field only) | in-culture |
| Endpoints measured | cell viability; TGF-β and SMAD7 expression; COL1A1 and COL1A2 expression |
| Pathways measured | TGF-β / SMAD |
| Research areas | Bone |
| Evidence tier | D — Cell, tissue or analytical |
| Publication types | Journal Article |
Appraisal
Each dimension is recorded separately and never combined into a single score. A study can be well controlled and still tell you little about people.
- Relevance to MOTS-c
- Direct
- Model applicability
- Cellular
- Sample size
- n/a
- Controls
- Appropriate
- Outcome validity
- Surrogate
- Support for its own conclusion
- Weak
Provenance
- Bibliographic fields retrieved from PubMed E-utilities efetch (title, journal, date, authors, DOI) on 2026-11-11.
- Annotated from the published abstract.
- Editorial review: approved (2026-11-11).
- Classification follows the site methodology; the record describes the study, not what MOTS-c does in people.